Navigation Links
AutoImmune Inc. Reports 2007 Third Quarter Financial Results
Date:11/8/2007

PASADENA, Calif., Nov. 8 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTCBB: AIMM) today reported a net loss of $8,000, or break even per share basic and diluted, for the three months ended September 30, 2007, compared with a net loss of $36,000, or break even per share basic and diluted, for the three months ended September 30, 2006. For the nine months ended September 30, 2007, the net loss was $62,000, or break even per share basic and diluted, compared with net loss of $517,000, or $0.03 per share basic and diluted for the same period in 2006. As of September 30, 2007, the Company reported $8.7 million in cash and marketable securities as compared to $8.8 million in cash and marketable securities as of December 31, 2006.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "Product sales at Colloral LLC, our joint venture with Deseret Laboratories, Inc., were disappointing in the quarter just ended, but we remain optimistic they will increase in coming months. While sales through GNC have ceased, Bronson Laboratories LLC is selling the product through its catalogs, and Colloral LLC began marketing the product through The Shopping Channel in Canada in early October." AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46 "Consolidation of Variable Interest Entities."

AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS Medical Corp., a Canadian company. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug MBP8298, if it reaches the market. BioMS recently reported that 70% of the patients screened for their first pivotal trial in secondary multiple sclerosis have the HLA-DR2/DR4 genes that are believed to make them responsive to therapy with MBP8298. Interim results from this trial are expected in May 2008.

AutoImmune is a biopharmaceutical company involved in the development of a new class of mucosally administered therapies for the treatment of autoimmune and cell-mediated inflammatory diseases and conditions.

This release contains forward-looking statements that involve risks and uncertainties. The Company's actual results may differ significantly from results discussed in the forward-looking statements due to a number of important factors, including, but not limited to the uncertainties of clinical trial results, the Company's dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed in the Company's most recent Annual Report on Form 10-KSB filed with the Securities and Exchange Commission in the section "Risk Factors" The discussion in the Annual Report on Form 10-KSB is hereby referenced into this release.

AUTOIMMUNE INC.

STATEMENT OF OPERATIONS

(Unaudited)

Three months ended Nine months ended

September 30, September 30,

2006 2007 2006 2007

Revenue $80,000 $59,000 $264,000 $219,000

Costs and expenses:

Cost of product revenue 5,000 9,000 18,000 20,000

Research and

development 25,000 7,000 172,000 95,000

Selling, general and

administrative 199,000 163,000 906,000 526,000

Total costs and

expenses 229,000 179,000 1,096,000 641,000

Interest income 113,000 112,000 315,000 335,000

Other income - - - 25,000

113,000 112,000 315,000 360,000

Net loss ($36,000) ($8,000) ($517,000) ($62,000)

Net loss per share -

basic ($0.00) ($0.00) ($0.03) ($0.00)

Net loss per share -

diluted ($0.00) ($0.00) ($0.03) ($0.00)

Weighted average common

shares outstanding -

basic 16,919,623 16,979,623 16,919,623 16,967,504

Weighted average common

shares outstanding -

diluted 16,919,623 16,979,623 16,919,623 16,967,504

CONDENSED BALANCE SHEET

(Unaudited)

December 31, September 30,

2006 2007

Cash and marketable securities $8,763,000 $8,692,000

Other current assets 188,000 311,000

Total assets $8,951,000 $9,003,000

Current liabilities $128,000 $149,000

Total stockholders' equity 8,823,000 8,854,000

Total liabilities and equity $8,951,000 $9,003,000


'/>"/>
SOURCE AutoImmune Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. M.D. Anderson-led team reports possible key to autoimmune disease
2. Occupational exposures may be linked to death from autoimmune disease
3. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
4. Haemacure Reports Third Quarter 2007 Results
5. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
6. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
7. MDS Reports Third Quarter 2007 Results
8. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
11. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new ... affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
(Date:6/23/2016)... Research and Markets has announced the addition ... States, China, Japan, Brazil, United Kingdom, Germany, France, Italy, ... Surgical Procedure Volumes: Global ... surgical procedure volume data in a geographic context. The ... of growth drivers and inhibitors, including world population growth, ...
Breaking Medicine Technology: